Santen Pharmaceutical Co Ltd released its earnings results on Nov 06, 2025. The company reported $0.166 earnings per share for the quarter, beating the consensus estimate of N/A by $0.166.

Is Santen Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Santen Pharmaceutical Co Ltd pay dividends?

Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.128 which represents an annual dividend yield of 2.02%. See more information on Santen Pharmaceutical Co Ltd dividends here

What is Santen Pharmaceutical Co Ltd’s EPS estimate?

Santen Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Santen Pharmaceutical Co Ltd have?

Santen Pharmaceutical Co Ltd has 322,268,550 shares outstanding.

What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?

Santen Pharmaceutical Co Ltd reported an EPS of $0.166 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.407%.

Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in SNPHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Santen Pharmaceutical Co Stock Smart Score

Underperform

Fundamentals

Return on Equity

10.89%

Trailing 12-Months

Asset Growth

4.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.